Last April 10th 2019, MabDesign and Lyonbiopole organized a day dedicated to the use of Artificial Intelligence to accelerate the development of Immunotherapies. This event gathered together nearly 80 stakeholders working in Artificial Intelligence applied to health, large groups developing immunotherapies that use these approaches, as well as academic laboratories, start-ups and biotechs that develop the latest innovations in the field. The event highlighted the place of Artificial Intelligence tools from the discovery phases of immunotherapy candidates (drug discovery, early stage, biomarker discovery, NGS), through bioproduction until their use during clinical trials (in silico trials, data management, diagnosis, personalized medicine).
Several experts shared their expertise on the subject during this day with contributions from Microsoft Health France, Institut Roche, Institut Curie, OWKIN, GE Healthcare LifeScience, Keen Eye, Léon Bérard Center, Novadiscovery, SOPHiA Genetics, Ariana Pharma, Guerbet and Gustave Roussy. Several companies have also showcased their latest innovations in the field, such as MAbSilico, Precision For Medicine, Soladis and Voxcan. The program has enabled to held 80 business meetings. To know more
